Status:
UNKNOWN
PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial
Lead Sponsor:
Sun Yat-sen University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease. However, less than 2...
Eligibility Criteria
Inclusion
- Diagnosed as potentially resectable with consensus by the panel of liver surgeons
- stage BCLC A/B/C, without extra-hepatic involvement
- No previous anti-HCC treatment
- Eastern Co-operative Group performance status 2 or less
- Liver function: Child's A or B (score \< 7)
Exclusion
- Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
- underlying serve cardiac or renal diseases Known or suspected allergy to the investigational agent or any agent given in association with this trial
- Patients ineligible for hepatic artery embolization, or PD-1 antibody
Key Trial Info
Start Date :
April 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2023
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT04814043
Start Date
April 20 2021
End Date
December 30 2023
Last Update
September 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060